{"id":"NCT05553366","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-10-03","primaryCompletion":"2023-12-15","completion":"2023-12-15","firstPosted":"2022-09-23","resultsPosted":"2025-08-01","lastUpdate":"2025-08-01"},"enrollment":1075,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Pain"],"interventions":[{"type":"DRUG","name":"SUZ","otherNames":["VX-548"]},{"type":"DRUG","name":"HB/APAP","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to SUZ)","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to HB/APAP)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Hydrocodone bitartrate/acetaminophen (HB/APAP)","type":"ACTIVE_COMPARATOR"},{"label":"Suzetrigine (SUZ)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.","primaryOutcome":{"measure":"Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo","timeFrame":"0 to 48 hours After First Dose of Study Drug","effectByArm":[{"arm":"Placebo","deltaMin":70.6,"sd":6.3},{"arm":"Suzetrigine (SUZ)","deltaMin":99.9,"sd":4.5}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":216},"commonTop":["Nausea","Headache","Dizziness","Constipation"]}}